par Berns, Katrien;Sonnenblick, Amir;Gennissen, Annemiek;Brohée, Sylvain 
;Hijmans, Marielle EM;Evers, Bastiaan;Fumagalli, Debora ;Desmedt, Christine ;Loibl, Sibylle;Denkert, Carsten;Neven, Patrick;Guo, Yue-Wei;Zhang, Fan ;Knijnenburg, Theo TA;Bosse, Tjalling;van der Heijden, Michiel MS;Hindriksen, Sanne;Nijkamp, Wouter;Wessels, Lodewyk LF;Joensuu, Heikki;Mills, Gordon B;Beijersbergen, Roderick RL;Sotiriou, Christos ;Bernards, René
Référence Clinical cancer research, 22, 21, page (5238-5248)
Publication Publié, 2016-11
;Hijmans, Marielle EM;Evers, Bastiaan;Fumagalli, Debora ;Desmedt, Christine ;Loibl, Sibylle;Denkert, Carsten;Neven, Patrick;Guo, Yue-Wei;Zhang, Fan ;Knijnenburg, Theo TA;Bosse, Tjalling;van der Heijden, Michiel MS;Hindriksen, Sanne;Nijkamp, Wouter;Wessels, Lodewyk LF;Joensuu, Heikki;Mills, Gordon B;Beijersbergen, Roderick RL;Sotiriou, Christos ;Bernards, RenéRéférence Clinical cancer research, 22, 21, page (5238-5248)
Publication Publié, 2016-11
Article révisé par les pairs
| Résumé : | Despite the substantial progress in the development of targeted anticancer drugs, treatment failure due to primary or acquired resistance is still a major hurdle in the effective treatment of most advanced human cancers. Understanding these resistance mechanisms will be instrumental to improve personalized cancer treatment. |
